Abstract Context The European Association of Urology Renal Cell Carcinoma Guideline
Panel recently conducted a systematic review of treatment options for patients with …

Context While vascular endothelial growth factor-targeted therapy and mammalian target of
rapamycin inhibition are effective strategies in treating clear cell renal cell carcinoma …

Objectives: To conduct a systematic review and network meta-analysis (NMA) to assess
effectiveness of first-line treatments for advanced renal cell carcinoma (RCC). Methods …

There is still no standard treatment for non‐clear cell renal cell carcinomas. Sunitinib is the
most examined drug because of its effectiveness in retrospective studies and clinical trials …

Context Clinical data supporting the use of targeted agents for the treatment of metastatic
renal cell carcinoma (RCC) are based predominantly on patients with clear cell histology …

The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the
clinical management of patients with clear cell and non-clear cell renal carcinoma. These …

Aim Non-clear cell renal cell carcinoma (nccRCC) tumours include a heterogeneous group
of malignancies that profoundly differ in terms of morphology, genetic profile, clinical …

Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous group of malignancies
that represents 25% of renal cell carcinoma (RCC) cases. Treatment for non-clear cell …

Background: Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still
an unmet clinical need, with few studies to support an evidence-based approach. To date …

Background Non-clear cell renal cell carcinomas are histologically and genetically diverse
kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We …